ArticleMolecular and clinical oncology2013
Peroxiredoxin V: A candidate breast tumor marker of population specificity.
Article in Molecular and clinical oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 15 citations in OpenAlex.
- Expression and prognostic value of PRDX family in colon adenocarcinoma by integrating comprehensive analysis andFrontiers in oncology · 2023Article
- Individualized Medicine in Africa: Bringing the Practice Into the Realms of Population Heterogeneity.Frontiers in genetics · 2022Article
- Overexpression of peroxiredoxin-3 and -5 is a potential biomarker for prognosis in endometrial cancer.Oncology letters · 2018Article
- Peroxiredoxin Involvement in the Initiation and Progression of Human Cancer.Antioxidants & redox signaling · 2018Review
- Neuroprotective mechanisms of rutin for spinal cord injury through anti-oxidation and anti-inflammation and inhibition of p38 mitogen activated protein kinase pathway.Neural regeneration research · 2018Article
- Roles of peroxiredoxins in cancer, neurodegenerative diseases and inflammatory diseases.Pharmacology & therapeutics · 2016Review
- The identification of goat peroxiredoxin-5 and the evaluation and enhancement of its stability by nanoparticle formation.Scientific reports · 2016Article
- Redox Homeostasis and Cellular Antioxidant Systems: Crucial Players in Cancer Growth and Therapy.Oxidative medicine and cellular longevity · 2016Review
- Part I: cancer in Sudan—burden, distribution, and trends breast, gynecological, and prostate cancers.Cancer medicine · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast and cervical cancers account for approximately 50% of all types of cancer in Sudanese women. In a previous preliminary proteomic study aimed to identify proteins that were differentially expressed between tumors and control tissues (n=24), we identified peroxiredoxin V (PrdxV) as a candidate tumor marker. Peroxiredoxins (Prdxs) are a family of multifunctional proteins that are involved in the cell protection against oxidative stress, modulation of intracellular signaling, and regulation of cell proliferation. Knockout animal models suggest that the regulation of these proteins may be a novel target for therapeutic interventions. A total of 91 tumors and 79 normal breast tissues obtained from a panel of 106 Sudanese breast cancer patients, as well as 31 paired tissue samples (tumors and controls) from Chinese cancer patients were included in this study. Tissue sections were examined using immunohistochemistry (IHC) for PrdxI, V and VI antibodies. The PrdxV mRNA pattern of expression was also investigated using
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.